Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Oral azacitidine improves overall survival in patients with AML in remission

Oral azacitidine improves overall survival in patients with AML in remission

Presented By
Dr Andrew Wei, Alfred Hospital, Australia
Conference
ASH 2019
Trial
Phase 3, QUAZAR AML-001
In a phase 3, randomised, placebo-controlled trial, a new oral formulation of azacitidine, called CC-486, significantly improved overall survival in patients with newly diagnosed acute myeloid leukaemia (AML) in remission after standard induction chemotherapy, with or without consolidation therapy. CC-486 had a favourable safety profile. Dr Andrew Wei (Alfred Hospital, Australia) presented the results of the QUAZAR AML-001 trial in the late-breaking session [1]. The study attempted to address the deficit of maintenance therapy options available to older AML patients who have achieved remission after initial chemotherapy and want to defer any further aggressive treatment, such as stem cell transplantation. AML patients with either intermediate-risk or poor-risk cytogenetics (n=472; age range 55-86 years) were enrolled if they had (1) achieved a complete response aft...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on